ArticleFrontiers in public health2024

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.

Zhiwei Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.